Skip to main content

Advertisement

Table 1 Demographic and clinical characteristics at the time of study of SLE and healthy controls

From: IL-37 inhibits the production of inflammatory cytokines in peripheral blood mononuclear cells of patients with systemic lupus erythematosus: its correlation with disease activity

Characteristics SLE patients (n = 66) Healthy controls (n = 41)
Age (years) 30.5 ± 8.02 (18-54) 31.8 ± 9.57 (19-58)
Sex (female/male) 59/7 37/4
Disease duration (years) 2.0 ± 1.12 -
Arthritis n (%) 3 (4.5) -
Renal diseases n (%) 40 (60.6) -
Fever n (%) 13 (19.7) -
Neurological disorder n (%) 1 (1.5) -
Leukopenia n (%) 11 (16.7) -
Thrombocytopenia n (%) 8 (12.1) -
Anti-ds-DNA antibody n (%) 39 (59.1) -
Anti-Smith antibody n (%) 30 (45.5) -
Anti-AnuA antibody n (%) 20 (30.3) -
Anti-rRNP antibody n (%) 11 (16.7) -
ESR 29.2 ± 27.80 -
Low C3 n (%) 33 (50.0) -
Low C4 n (%) 29 (43.9) -
IgG (g/L) 16.2 ± 5.63 -
IgM (g/L) 1.21 ± 0.64 -
IgA (g/L) 2.33 ± 1.09 -
SLEDAI (2-14) 6.34 ± 3.26 -
  1. Except where otherwise indicated, values are expressed as mean ± standard deviation. There were no significant differences between patients with SLE and healthy donors in terms of age and sex. Anti-ds-DNA antibody, anti-double stranded DNA antibody; Anti-Smith antibody, anti-smith-antibody; Anti-AnuA antibody, anti-nucleosome antibody; Anti-rRNP antibody, Anti-Ribosomal RNP Antibody; ESR, erythrocyte sedimentation rate; C3, complement 3; C4, complement 4; IgG, Immunoglobulin G; IgM, Immunoglobulin M; IgA, Immunoglobulin A; SLE, systemic lupus erythematosus; SLEDAI, SLE disease activity index.